Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphomaJeremy S. Abramson, Celeste Bello, Donna Neuberg et al.|Blood|2019Cited by 51
Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial.Jeremy S. Abramson, Celeste Bello, Jon Arnason et al.|Journal of Clinical Oncology|2015Cited by 14
A phase I–II study of rituximab, ifosfamide, mitoxantrone andetoposide (R-IME) for B cell non-Hodgkin’s lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT)Robin Joyce, David Avigan, Meredith M. Regan et al.|Annals of Oncology|2003Cited by 13
Yttrium-90 Ibritumomab Tiuxetan Followed by Rituximab Maintenance as Treatment for Patients with Diffuse Large B-Cell Lymphoma Are Not Candidates for Autologous Stem Cell TransplantJon Arnason, Robin Joyce, Katarina Luptakova et al.|Acta Haematologica|2015Cited by 11